AstraZeneca supports the growth of the C3i Lymphoma Registry, a project lead by Dr. Isabelle Fleury at Hôpital Maisonneuve-Rosemont
Montreal, December 16, 2021 — The C3i Center (C3i) is proud to announce the participation of AstraZeneca Canada (AstraZeneca) in supporting the development of the… Read More »
MONTRÉAL QC, November 4, 2021 – C3i Center Inc. has strengthened our position as Canada’s leading one-stop contract development and manufacturing organization operating in the… Read More »
C3i Center Inc. Supports the Manufacturing of the First Canadian-Made CAR-T Cell Therapy for the Treatment of Solid Tumours
An innovative treatment for advanced metastatic HER2-positive tumours has been administered to the first patient in a phase I/II clinical trial. The investigational T-cell antigen… Read More »
C3i Center Inc (Formerly known Centre for Commercialisation of Cancer Immunotherapy) is proud to announce three new additions to its executive team. Louisa Petropoulos has… Read More »
We’re on a mission to build Canada’s capacity for commercializing cell therapies to benefit our health and economy. Join our cutting-edge team today!
Behind every triumphant headline announcing a new breakthrough medicine, there’s an often untold story of years or even decades of basic research in the lab,… Read More »